Cargando…
Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity
Enteric viruses exploit bacterial components, including lipopolysaccharides (LPS) and peptidoglycan (PG), to facilitate infection in humans. Because of their origin in the bat enteric system, we wondered if severe acute respiratory syndrome coronavirus (SARS-CoV) or Middle East respiratory syndrome...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819921/ https://www.ncbi.nlm.nih.gov/pubmed/31462558 http://dx.doi.org/10.1128/JVI.01282-19 |
_version_ | 1783463843250307072 |
---|---|
author | Johnson, Bryan A. Hage, Adam Kalveram, Birte Mears, Megan Plante, Jessica A. Rodriguez, Sergio E. Ding, Zhixia Luo, Xuemei Bente, Dennis Bradrick, Shelton S. Freiberg, Alexander N. Popov, Vsevolod Rajsbaum, Ricardo Rossi, Shannan Russell, William K. Menachery, Vineet D. |
author_facet | Johnson, Bryan A. Hage, Adam Kalveram, Birte Mears, Megan Plante, Jessica A. Rodriguez, Sergio E. Ding, Zhixia Luo, Xuemei Bente, Dennis Bradrick, Shelton S. Freiberg, Alexander N. Popov, Vsevolod Rajsbaum, Ricardo Rossi, Shannan Russell, William K. Menachery, Vineet D. |
author_sort | Johnson, Bryan A. |
collection | PubMed |
description | Enteric viruses exploit bacterial components, including lipopolysaccharides (LPS) and peptidoglycan (PG), to facilitate infection in humans. Because of their origin in the bat enteric system, we wondered if severe acute respiratory syndrome coronavirus (SARS-CoV) or Middle East respiratory syndrome CoV (MERS-CoV) also use bacterial components to modulate infectivity. To test this question, we incubated CoVs with LPS and PG and evaluated infectivity, finding no change following LPS treatment. However, PG from Bacillus subtilis reduced infection >10,000-fold, while PG from other bacterial species failed to recapitulate this. Treatment with an alcohol solvent transferred inhibitory activity to the wash, and mass spectrometry revealed surfactin, a cyclic lipopeptide antibiotic, as the inhibitory compound. This antibiotic had robust dose- and temperature-dependent inhibition of CoV infectivity. Mechanistic studies indicated that surfactin disrupts CoV virion integrity, and surfactin treatment of the virus inoculum ablated infection in vivo. Finally, similar cyclic lipopeptides had no effect on CoV infectivity, and the inhibitory effect of surfactin extended broadly to enveloped viruses, including influenza, Ebola, Zika, Nipah, chikungunya, Una, Mayaro, Dugbe, and Crimean-Congo hemorrhagic fever viruses. Overall, our results indicate that peptidoglycan-associated surfactin has broad viricidal activity and suggest that bacteria by-products may negatively modulate virus infection. IMPORTANCE In this article, we consider a role for bacteria in shaping coronavirus infection. Taking cues from studies of enteric viruses, we initially investigated how bacterial surface components might improve CoV infection. Instead, we found that peptidoglycan-associated surfactin is a potent viricidal compound that disrupts virion integrity with broad activity against enveloped viruses. Our results indicate that interactions with commensal bacterial may improve or disrupt viral infections, highlighting the importance of understanding these microbial interactions and their implications for viral pathogenesis and treatment. |
format | Online Article Text |
id | pubmed-6819921 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-68199212020-04-24 Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity Johnson, Bryan A. Hage, Adam Kalveram, Birte Mears, Megan Plante, Jessica A. Rodriguez, Sergio E. Ding, Zhixia Luo, Xuemei Bente, Dennis Bradrick, Shelton S. Freiberg, Alexander N. Popov, Vsevolod Rajsbaum, Ricardo Rossi, Shannan Russell, William K. Menachery, Vineet D. J Virol Vaccines and Antiviral Agents Enteric viruses exploit bacterial components, including lipopolysaccharides (LPS) and peptidoglycan (PG), to facilitate infection in humans. Because of their origin in the bat enteric system, we wondered if severe acute respiratory syndrome coronavirus (SARS-CoV) or Middle East respiratory syndrome CoV (MERS-CoV) also use bacterial components to modulate infectivity. To test this question, we incubated CoVs with LPS and PG and evaluated infectivity, finding no change following LPS treatment. However, PG from Bacillus subtilis reduced infection >10,000-fold, while PG from other bacterial species failed to recapitulate this. Treatment with an alcohol solvent transferred inhibitory activity to the wash, and mass spectrometry revealed surfactin, a cyclic lipopeptide antibiotic, as the inhibitory compound. This antibiotic had robust dose- and temperature-dependent inhibition of CoV infectivity. Mechanistic studies indicated that surfactin disrupts CoV virion integrity, and surfactin treatment of the virus inoculum ablated infection in vivo. Finally, similar cyclic lipopeptides had no effect on CoV infectivity, and the inhibitory effect of surfactin extended broadly to enveloped viruses, including influenza, Ebola, Zika, Nipah, chikungunya, Una, Mayaro, Dugbe, and Crimean-Congo hemorrhagic fever viruses. Overall, our results indicate that peptidoglycan-associated surfactin has broad viricidal activity and suggest that bacteria by-products may negatively modulate virus infection. IMPORTANCE In this article, we consider a role for bacteria in shaping coronavirus infection. Taking cues from studies of enteric viruses, we initially investigated how bacterial surface components might improve CoV infection. Instead, we found that peptidoglycan-associated surfactin is a potent viricidal compound that disrupts virion integrity with broad activity against enveloped viruses. Our results indicate that interactions with commensal bacterial may improve or disrupt viral infections, highlighting the importance of understanding these microbial interactions and their implications for viral pathogenesis and treatment. American Society for Microbiology 2019-10-29 /pmc/articles/PMC6819921/ /pubmed/31462558 http://dx.doi.org/10.1128/JVI.01282-19 Text en Copyright © 2019 American Society for Microbiology. This article is made available via the PMC Open Access Subset for unrestricted noncommercial re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Vaccines and Antiviral Agents Johnson, Bryan A. Hage, Adam Kalveram, Birte Mears, Megan Plante, Jessica A. Rodriguez, Sergio E. Ding, Zhixia Luo, Xuemei Bente, Dennis Bradrick, Shelton S. Freiberg, Alexander N. Popov, Vsevolod Rajsbaum, Ricardo Rossi, Shannan Russell, William K. Menachery, Vineet D. Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity |
title | Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity |
title_full | Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity |
title_fullStr | Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity |
title_full_unstemmed | Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity |
title_short | Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity |
title_sort | peptidoglycan-associated cyclic lipopeptide disrupts viral infectivity |
topic | Vaccines and Antiviral Agents |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819921/ https://www.ncbi.nlm.nih.gov/pubmed/31462558 http://dx.doi.org/10.1128/JVI.01282-19 |
work_keys_str_mv | AT johnsonbryana peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity AT hageadam peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity AT kalverambirte peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity AT mearsmegan peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity AT plantejessicaa peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity AT rodriguezsergioe peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity AT dingzhixia peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity AT luoxuemei peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity AT bentedennis peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity AT bradricksheltons peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity AT freibergalexandern peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity AT popovvsevolod peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity AT rajsbaumricardo peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity AT rossishannan peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity AT russellwilliamk peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity AT menacheryvineetd peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity |